Tags

Type your tag names separated by a space and hit enter

IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan.
J Clin Aesthet Dermatol. 2019 Dec; 12(12):E53-E57.JC

Abstract

Objective:

We assessed clinical effectiveness, longevity of treatment effects, and patient satisfaction with incobotulinumtoxinA for glabellar frown lines (GFL) treatment in Asian patients. Design, Setting, and

Participants:

This was a prospective, multicenter, single-arm, open-label study at six sites in Taiwan. Patients aged 20 to 65 years with mild to very severe GFLs (Merz scale: 1-4 points) were eligible; 45 patients [including 23 BoNT/A-naïve and 22 previously-treated ("switch") patients were enrolled. Patients received intramuscular incobotulinumtoxinA injection at up to five injection points. Total doses ranged from 12 to 20U. Measurements: Investigators assessed improvements in dynamic GFLs at Days 14 and 120 using the validated five-point Merz scale (0=no lines; 4=very severe lines). Treatment satisfaction was self-reported by patients via questionnaire.

Results:

All patients showed excellent response to treatment in that Merz scores at Day 14 were 0 or 1 point(s). Both groups showed a mean improvement of 2.9 points; the response rate (1-point improvement or more from baseline) was 100 percent. GFL improvement was maintained over at least four months in both groups (mean improvements at Day 120: 1.5 points, naïve; 1.7 points, switch). Patient satisfaction ratings remained high (almost 100% in both groups) throughout the study. There were no statistically significant differences between groups regarding treatment satisfaction or GFL improvement (Merz score) at Days 14 and 120. No adverse events occurred.

Conclusion:

In Asian patients, incobotulinumtoxinA treatment for dynamic GFLs is effective and long lasting, with no expected differences between BoNT/A-naïve patients and those switching from other BoNT/As. IncobotulinumtoxinA yields consistent and natural-looking results for first and subsequent treatments.

Authors+Show Affiliations

Dr. Chao is with the CHAO Institute of Aesthetic Medicine in Taipei, Taiwan. Dr. Tseng is with the Milano Aesthetic Clinic in Taipei, Taiwan. Dr. Yang is with the MED Aesthetic Clinic in Kaohsiung, Taiwan. Dr. Chen is with the YaSkin Dermatology Clinic in Kaohsiung, Taiwan. Dr. Hsu is with the Nai Jen Hsu Dermatology Clinic in Tainan, Taiwan. Dr. Chang is with Liyen's Clinic of Plastic Surgery in Taichung, Taiwan.Dr. Chao is with the CHAO Institute of Aesthetic Medicine in Taipei, Taiwan. Dr. Tseng is with the Milano Aesthetic Clinic in Taipei, Taiwan. Dr. Yang is with the MED Aesthetic Clinic in Kaohsiung, Taiwan. Dr. Chen is with the YaSkin Dermatology Clinic in Kaohsiung, Taiwan. Dr. Hsu is with the Nai Jen Hsu Dermatology Clinic in Tainan, Taiwan. Dr. Chang is with Liyen's Clinic of Plastic Surgery in Taichung, Taiwan.Dr. Chao is with the CHAO Institute of Aesthetic Medicine in Taipei, Taiwan. Dr. Tseng is with the Milano Aesthetic Clinic in Taipei, Taiwan. Dr. Yang is with the MED Aesthetic Clinic in Kaohsiung, Taiwan. Dr. Chen is with the YaSkin Dermatology Clinic in Kaohsiung, Taiwan. Dr. Hsu is with the Nai Jen Hsu Dermatology Clinic in Tainan, Taiwan. Dr. Chang is with Liyen's Clinic of Plastic Surgery in Taichung, Taiwan.Dr. Chao is with the CHAO Institute of Aesthetic Medicine in Taipei, Taiwan. Dr. Tseng is with the Milano Aesthetic Clinic in Taipei, Taiwan. Dr. Yang is with the MED Aesthetic Clinic in Kaohsiung, Taiwan. Dr. Chen is with the YaSkin Dermatology Clinic in Kaohsiung, Taiwan. Dr. Hsu is with the Nai Jen Hsu Dermatology Clinic in Tainan, Taiwan. Dr. Chang is with Liyen's Clinic of Plastic Surgery in Taichung, Taiwan.Dr. Chao is with the CHAO Institute of Aesthetic Medicine in Taipei, Taiwan. Dr. Tseng is with the Milano Aesthetic Clinic in Taipei, Taiwan. Dr. Yang is with the MED Aesthetic Clinic in Kaohsiung, Taiwan. Dr. Chen is with the YaSkin Dermatology Clinic in Kaohsiung, Taiwan. Dr. Hsu is with the Nai Jen Hsu Dermatology Clinic in Tainan, Taiwan. Dr. Chang is with Liyen's Clinic of Plastic Surgery in Taichung, Taiwan.Dr. Chao is with the CHAO Institute of Aesthetic Medicine in Taipei, Taiwan. Dr. Tseng is with the Milano Aesthetic Clinic in Taipei, Taiwan. Dr. Yang is with the MED Aesthetic Clinic in Kaohsiung, Taiwan. Dr. Chen is with the YaSkin Dermatology Clinic in Kaohsiung, Taiwan. Dr. Hsu is with the Nai Jen Hsu Dermatology Clinic in Tainan, Taiwan. Dr. Chang is with Liyen's Clinic of Plastic Surgery in Taichung, Taiwan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32038766

Citation

Chao, Yates Yen-Yu, et al. "IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: a Prospective, Multicenter, Single-arm Study in Taiwan." The Journal of Clinical and Aesthetic Dermatology, vol. 12, no. 12, 2019, pp. E53-E57.
Chao YY, Tseng FW, Yang YL, et al. IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan. J Clin Aesthet Dermatol. 2019;12(12):E53-E57.
Chao, Y. Y., Tseng, F. W., Yang, Y. L., Chen, Y. H., Hsu, N. J., & Chang, L. Y. (2019). IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan. The Journal of Clinical and Aesthetic Dermatology, 12(12), E53-E57.
Chao YY, et al. IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: a Prospective, Multicenter, Single-arm Study in Taiwan. J Clin Aesthet Dermatol. 2019;12(12):E53-E57. PubMed PMID: 32038766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan. AU - Chao,Yates Yen-Yu, AU - Tseng,Fang-Wen, AU - Yang,Yu-Li, AU - Chen,Ya-Hui, AU - Hsu,Nai-Jen, AU - Chang,Li-Yen, Y1 - 2019/12/01/ PY - 2020/2/11/entrez PY - 2020/2/11/pubmed PY - 2020/2/11/medline KW - Asian KW - Botulinum neurotoxin type A KW - glabellar frown lines KW - incobotulinumtoxinA KW - patient satisfaction SP - E53 EP - E57 JF - The Journal of clinical and aesthetic dermatology JO - J Clin Aesthet Dermatol VL - 12 IS - 12 N2 - Objective: We assessed clinical effectiveness, longevity of treatment effects, and patient satisfaction with incobotulinumtoxinA for glabellar frown lines (GFL) treatment in Asian patients. Design, Setting, and Participants: This was a prospective, multicenter, single-arm, open-label study at six sites in Taiwan. Patients aged 20 to 65 years with mild to very severe GFLs (Merz scale: 1-4 points) were eligible; 45 patients [including 23 BoNT/A-naïve and 22 previously-treated ("switch") patients were enrolled. Patients received intramuscular incobotulinumtoxinA injection at up to five injection points. Total doses ranged from 12 to 20U. Measurements: Investigators assessed improvements in dynamic GFLs at Days 14 and 120 using the validated five-point Merz scale (0=no lines; 4=very severe lines). Treatment satisfaction was self-reported by patients via questionnaire. Results: All patients showed excellent response to treatment in that Merz scores at Day 14 were 0 or 1 point(s). Both groups showed a mean improvement of 2.9 points; the response rate (1-point improvement or more from baseline) was 100 percent. GFL improvement was maintained over at least four months in both groups (mean improvements at Day 120: 1.5 points, naïve; 1.7 points, switch). Patient satisfaction ratings remained high (almost 100% in both groups) throughout the study. There were no statistically significant differences between groups regarding treatment satisfaction or GFL improvement (Merz score) at Days 14 and 120. No adverse events occurred. Conclusion: In Asian patients, incobotulinumtoxinA treatment for dynamic GFLs is effective and long lasting, with no expected differences between BoNT/A-naïve patients and those switching from other BoNT/As. IncobotulinumtoxinA yields consistent and natural-looking results for first and subsequent treatments. SN - 1941-2789 UR - https://www.unboundmedicine.com/medline/citation/32038766/IncobotulinumtoxinA_for_the_Treatment_of_Glabellar_Frown_Lines:_A_Prospective,_Multicenter,_Single-arm_Study_in_Taiwan L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32038766/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.